US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% SDEV $7.48 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00%
FinancialContent

Articles published by Veradermics, Incorporated

News headline image
Veradermics to Present at Upcoming September Investor Conferences
From Veradermics, Incorporated
Via Business Wire
Tickers MANE
News headline image
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
From Veradermics, Incorporated
Via Business Wire
Tickers MANE
News headline image
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
From Veradermics, Incorporated
Via Business Wire
Tickers MANE
News headline image
Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout
From Veradermics, Incorporated
Via Business Wire
Tickers MANE
News headline image
Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss
From Veradermics, Incorporated
Via Business Wire
Tickers MANE
News headline image
Veradermics to Present at Upcoming June Investor Conferences
From Veradermics, Incorporated
Via Business Wire
Tickers MANE
News headline image
Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research
From Veradermics, Incorporated
Via Business Wire
Tickers MANE
News headline image
Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
From Veradermics, Incorporated
Via Business Wire
Tickers MANE
News headline image
Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
From Veradermics, Incorporated
Via Business Wire
Tickers MANE
News headline image
Veradermics Announces Pricing of Upsized Public Offering and Private Placement
From Veradermics, Incorporated
Via Business Wire
Tickers MANE
News headline image
Veradermics Announces Launch of Public Offering
From Veradermics, Incorporated
Via Business Wire
Tickers MANE
News headline image
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
From Veradermics, Incorporated
Via Business Wire
Tickers MANE
News headline image
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
From Veradermics, Incorporated
Via Business Wire
Tickers MANE
News headline image
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting
From Veradermics, Incorporated
Via Business Wire
Tickers MANE
News headline image
Veradermics to Participate in Upcoming March Investor Conferences
From Veradermics, Incorporated
Via Business Wire
Tickers MANE
News headline image
Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss
From Veradermics, Incorporated
Via Business Wire
Tickers MANE
News headline image
Veradermics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
From Veradermics, Incorporated
Via Business Wire
Tickers MANE
News headline image
Veradermics Announces Pricing of Upsized Initial Public Offering
From Veradermics, Incorporated
Via Business Wire